Genzyme’s Once-Daily, Oral AUBAGIO® Approved in Australia for Treatment of Relapsing Multiple Sclerosis

[Business Wire] – CAMBRIDGE, Mass.–(BUSINESSWIRE)– Genzyme , a Sanofi company, (EURONEXT: SAN and NYSE: SNY) announced today that the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO ® (teriflunomide) … more

View todays social media effects on SAN

View the latest stocks trending across Twitter. Click to view dashboard